A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy

Trial Profile

A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2017

At a glance

  • Drugs Candesartan cilexetil/nifedipine (Primary) ; Nifedipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 26 Jan 2017 Status changed from recruiting to completed.
    • 12 Oct 2013 Planned End Date changed from 29 May 2013 to 2 Jul 2014 as reported by European Clinical Trials Database.
    • 04 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top